The objective of this randomized double-blinded, placebo-controlled Phase II trial is to examine the effects of pravastatin use versus placebo after 12 months of treatment on hepatocellular cancer (HCC) recurrence in 180 patients with liver cirrhosis, HCC meeting Milan Criteria for tumor burden, and initial locoregional therapy (LRT) with complete response.